GSK’s FLUARIX QUADRIVALENT exemplifies 63.2% efficacy

GSK presented at the Center for Disease Control and Prevention Advisory Committee on Immunization Practices meeting that FLUARIX QUADRIVALENT exhibited 63.2% efficacy against moderate to severe influenza of any severity in children 6 months through 35 months of age.

Results were based on a randomized, observer-blind, non-influenza vaccine-controlled trial that enlisted 12,018 children in 5 independent cohorts in 13 countries in Asia, Europe and Central America from 2011 through the end of 2014.

Dr. Leonard Friedland, Vice President, Scientific Affairs and Public Health, GSK Vaccines, who presented the data to the ACIP. claimed “FLUARIX QUADRIVALENT can help ensure health care provider and parents have the ability to help protect young children against the flu.”

The safety and reactogenicity profile was similar to vaccines used in the same age group. No safety signal was observed. FLUARIX QUADRIVALENT was immunogenic against all four vaccine strains

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons aged 6 months and older.